

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934  
Date of Report (Date of earliest event reported): December 31, 2024**

**Aspira Women's Health Inc.**  
(Exact name of Registrant as Specified in Its Charter)

**Delaware  
(State or Other Jurisdiction  
of Incorporation)**

**001-34810  
(Commission  
File Number)**

**33-0595156  
(IRS Employer  
Identification No.)**

**12117 Bee Caves Road  
Building III  
Suite 100  
Austin, Texas  
(Address of Principal Executive Offices)**

**78738  
(Zip Code)**

**Registrant's Telephone Number, Including Area Code: 512 519-0400**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

<b>Title of each class</b>	<b>Trading Symbol(s)</b>	<b>Name of each exchange on which registered</b>
Common Stock, par value \$0.001 per share	AWH	The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.**

As Aspira Women's Health Inc. (the "Company") previously disclosed in its Current Report on Form 8-K filed with the Securities and Exchange Commission on July 5, 2024, on July 1, 2024, the Company received written notice (the "Notice") from the Listing Qualifications Staff (the "Staff") of the Nasdaq Stock Market, LLC ("Nasdaq") notifying the Company that for the 30 consecutive business days preceding the date of the Notice, the Company's Market Value of Listed Securities was below the minimum of \$35 million required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the "MVLS Requirement"). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), Nasdaq provided the Company with 180 calendar days, or until December 30, 2024 (the "Compliance Date"), to regain compliance with the MVLS Requirement.

On December 31, 2024, the Company received written notice from the Staff of Nasdaq notifying it that the Company failed to regain compliance with the MVLS Requirement by the Compliance Date. As such, unless the Company requests an appeal of Nasdaq's determination to delist the Company's common stock from The Nasdaq Capital Market by January 7, 2025 and pays Nasdaq a hearing fee of \$20,000, the Company's common stock will be delisted from The Nasdaq Capital Market at the opening of business on January 10, 2025. While the Company intends to appeal Nasdaq's decision, no guarantee can be provided that it will be successful in doing so and that its common stock will continue to be listed on The Nasdaq Capital Market. A request for an appeal will stay the delisting of the Company's common stock pending Nasdaq's decision.

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Aspira Women's Health Inc.

Date: December 31, 2024

By: /s/ Sandra Milligan

Sandra Milligan, Interim Chief Executive Officer